Drug profile · INN
imlifidase
IDEFIRIX
imlifidase (IDEFIRIX) is a antibodies hydrolytic enzyme.
Drug details — imlifidase
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
imlifidase (IDEFIRIX) is a antibodies hydrolytic enzyme.
Key facts
Mechanism of action
Antibodies hydrolytic enzyme
Primary target: Antibodies
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB
SERB Pharmaceuticals has entered into an agreement to acquire the European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma AB. This strategic acquisition aims to expand SERB's rare disease portfolio.
Hansa Licenses Idefirix to SERB for $133M: Implications for Investors
Hansa Biopharma has licensed Idefirix to SERB for $133 million. This deal marks a significant milestone in the drug's clinical development and investment landscape.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is imlifidase?
imlifidase (IDEFIRIX) is a antibodies hydrolytic enzyme.
What is the brand name for imlifidase?
IDEFIRIX is a marketed brand name for imlifidase. Check FDA Drugs@FDA for the current US label holder and prescribing information.